Melanoma remains a formidable challenge in oncology, particularly in its advanced stages.
Health Professionals
Flow Cytometry Can Reliably Identify CTC in Melanoma
Flow cytometry effectively detects CTCs in melanoma patients, offering a rapid, cost-effective alternative to molecular biology.
Treatment Gaps Persist in Advanced Melanoma as Trials Explore Options Beyond Standard Checkpoint and BRAF/MEK Inhibitors
Although dual checkpoint inhibition remains the preferred frontline approach for patients with BRAF-mutated, advanced-stage melanoma, there is a significant need for effective treatment alternatives for those who are refractory to, ineligible for, or did not respond to standard checkpoint blockade.
Use of Niraparib in Patients With Advanced Melanoma
Researchers may have uncovered early indications of the clinical benefit of niraparib in patients with advanced melanoma whose tumors have specific genetic changes impacting DNA repair, according to a recent study published by Kim et al in JCO Precision Oncology.